BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 27487294)

  • 1. Metformin and Angiogenesis in Cancer - Revisited.
    Kannarkatt J; Alkharabsheh O; Tokala H; Dimitrov NV
    Oncology; 2016; 91(4):179-184. PubMed ID: 27487294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics.
    Fuso Nerini I; Cesca M; Bizzaro F; Giavazzi R
    Chin J Cancer; 2016 Jun; 35(1):61. PubMed ID: 27357621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular normalization: a real benefit?
    Ribatti D
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):275-8. PubMed ID: 21638121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
    Grothey A; Ellis LM
    Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Are antiangiogenic antibodies universal for solid tumor?].
    Ray-Coquard I; Bachelot T; Saba C; Confavreux C; Brantus JF; Rustam F; Ghesquière H; Sebban C; Biron P; Guastalla JP; Blay JY
    Bull Cancer; 2007 Jul; 94 Spec No():S191-6. PubMed ID: 17846004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiangiogenic therapy for cancer: current and emerging concepts.
    Jain RK
    Oncology (Williston Park); 2005 Apr; 19(4 Suppl 3):7-16. PubMed ID: 15934498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
    Kerbel RS
    Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiogenesis. A boost for tumor starvation.
    Marx J
    Science; 2003 Jul; 301(5632):452-4. PubMed ID: 12881543
    [No Abstract]   [Full Text] [Related]  

  • 9. The combination of antiangiogenic therapy with other modalities.
    O'Reilly MS
    Cancer J; 2002; 8 Suppl 1():S89-99. PubMed ID: 12075706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.
    Jain RK
    Science; 2005 Jan; 307(5706):58-62. PubMed ID: 15637262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiangiogenesis and vascular disrupting agents in cancer: circumventing resistance and augmenting their therapeutic utility.
    Close A
    Future Med Chem; 2016; 8(4):443-62. PubMed ID: 26933926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Inhibition of angiogenesis by proteins, peptides and "small molecules"].
    Jayson G; Armand JP; Berdel WE
    Onkologie; 2005 Oct; 28 Suppl 4():29-34. PubMed ID: 16205103
    [No Abstract]   [Full Text] [Related]  

  • 13. Tumor angiogenesis and vascular normalization: alternative therapeutic targets.
    Viallard C; Larrivée B
    Angiogenesis; 2017 Nov; 20(4):409-426. PubMed ID: 28660302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiangiogenic strategies and agents in clinical trials.
    Rosen L
    Oncologist; 2000; 5 Suppl 1():20-7. PubMed ID: 10804087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiangiogenic therapy at a crossroads: clinical trial results and future directions.
    Ellis LM
    J Clin Oncol; 2003 Dec; 21(23 Suppl):281s-283s. PubMed ID: 14645411
    [No Abstract]   [Full Text] [Related]  

  • 16. The interaction of radiation therapy and antiangiogenic therapy.
    O'Reilly MS
    Cancer J; 2008; 14(4):207-13. PubMed ID: 18677126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiangiogenic therapy: a universal chemosensitization strategy for cancer?
    Kerbel RS
    Science; 2006 May; 312(5777):1171-5. PubMed ID: 16728631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic targeting of the tumor vasculature.
    Tozer GM; Bicknell R
    Semin Radiat Oncol; 2004 Jul; 14(3):222-32. PubMed ID: 15254865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Realizing the Potential of Vascular Targeted Therapy: The Rationale for Combining Vascular Disrupting Agents and Anti-Angiogenic Agents to Treat Cancer.
    Siemann DW; Chaplin DJ; Horsman MR
    Cancer Invest; 2017 Sep; 35(8):519-534. PubMed ID: 28872367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiangiogenic agents in breast cancer.
    Salter JT; Miller KD
    Cancer Invest; 2007 Oct; 25(7):518-26. PubMed ID: 18027149
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.